1233515-93-9
Chemical Structure
Remogliflozin etabonate-d7
Synonym(s): GSK189075-d7
- CAS No.: 1233515-93-9
- Formula:C26H31D7N2O9
- Molecular Weight:529.63
InChIKey: UAOCLDQAQNNEAX-HTUIKJHASA-N
SMILES: O=C(OCC)OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=NN(C(C)C)C(C)=C2CC3=CC=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C=C3)O1
Biological Activity: Remogliflozin etabonate-d7 (GSK189075-d7) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Remogliflozin etabonate-d7 | Remogliflozin etabonate-d7 (GSK189075-d7) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Remogliflozin etabonate | 99.64% | Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
